
Annual report 2025
added 02-19-2026
Pulse Biosciences Cash Flow 2011-2026 | PLSE
Annual Cash Flow Pulse Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-54.1 M | -36.3 M | -33 M | -47 M | -54.1 M | -35.4 M | -34.2 M | -23.9 M | -11.1 M | -8.05 M | -3.32 M | - | - | - | - |
Depreciation & Amortization |
406 K | 512 K | 542 K | 690 K | 480 K | 430 K | 494 K | 645 K | 336 K | 94 K | 51 K | - | - | - | - |
Accounts Payables |
2.78 M | 1.67 M | 1.84 M | 1.57 M | 2.9 M | 1.72 M | 1.96 M | 1.27 M | 782 K | 265 K | - | - | - | - | - |
Accounts Receivables |
274 K | - | - | - | 61 K | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
136 K | - | - | - | 5.82 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Pulse Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -13.5 M | - | - | - | -9.78 M | - | - | - | -6.57 M | - | -39 M | -28.4 M | -15.6 M | - | -41.4 M | -28.1 M | -11.7 M | - | -26.1 M | -17.6 M | -9.62 M | - | -25 M | -17 M | -7.33 M | - | -17.6 M | -10.7 M | -5.02 M | - | -7.12 M | -3.71 M | -2.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
100 K | 100 K | 117 K | - | 100 K | 100 K | 132 K | - | 100 K | 100 K | 135 K | - | 200 K | 100 K | 160 K | - | 100 K | 100 K | 113 K | - | 100 K | 100 K | 104 K | 167 K | 100 K | 100 K | 162 K | 166 K | 200 K | 200 K | 153 K | 166 K | 100 K | 25 K | 24 K | 167 K | 25 K | 24 K | 22 K | 167 K | 11 K | 10 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
2.98 M | 2.74 M | 2.37 M | 1.67 M | 1.73 M | 1.64 M | 1.71 M | 1.84 M | 1.41 M | 1.79 M | 2.16 M | 1.57 M | 2.02 M | 1.95 M | 3.49 M | 1.84 M | 2.71 M | 2.82 M | 2.16 M | 1.72 M | 1.72 M | 1.72 M | 1.72 M | 1.96 M | 1.96 M | 1.96 M | 1.96 M | 1.27 M | 1.27 M | 1.27 M | 1.27 M | 782 K | 782 K | 782 K | 782 K | 265 K | 265 K | 265 K | 265 K | 262 K | 262 K | 262 K | 262 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
15 K | - | - | - | - | - | - | - | - | - | - | - | 5 K | 8 K | 21 K | 61 K | 72 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
57 K | 51 K | 30 K | - | - | - | - | - | - | - | - | - | 750 K | 7.87 M | 7.49 M | 5.82 M | 4.28 M | 2.69 M | 1.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Pulse Biosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Ekso Bionics Holdings
EKSO
|
$ 10.93 | 9.3 % | $ 26.5 M | ||
|
AtriCure
ATRC
|
$ 30.98 | -1.53 % | $ 1.48 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
$ 81.35 | -2.42 % | $ 16.2 B | ||
|
Alcon
ALC
|
$ 83.71 | 0.76 % | $ 40.4 B | ||
|
iRhythm Technologies
IRTC
|
$ 127.95 | 1.67 % | $ 4.09 B | ||
|
Repro Med Systems
KRMD
|
$ 4.89 | 2.52 % | $ 223 M | ||
|
LeMaitre Vascular
LMAT
|
$ 107.13 | -0.67 % | $ 2.43 B | ||
|
Masimo Corporation
MASI
|
$ 175.43 | 0.04 % | $ 9.35 B | ||
|
Microbot Medical
MBOT
|
$ 2.5 | 4.57 % | $ 25.5 M | ||
|
Baxter International
BAX
|
$ 19.15 | 0.71 % | $ 9.82 B | ||
|
Glaukos Corporation
GKOS
|
$ 115.84 | -1.62 % | $ 5.61 B | ||
|
Haemonetics Corporation
HAE
|
$ 65.22 | -0.62 % | $ 3.28 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Harvard Bioscience
HBIO
|
$ 0.58 | 2.28 % | $ 24.6 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 171.09 | -1.87 % | $ 49.2 B | ||
|
ResMed
RMD
|
$ 258.17 | -0.04 % | $ 37.7 B | ||
|
Retractable Technologies
RVP
|
$ 0.67 | -3.6 % | $ 20.1 M | ||
|
AngioDynamics
ANGO
|
$ 10.97 | -0.68 % | $ 448 M | ||
|
BioLife Solutions
BLFS
|
$ 20.41 | 1.17 % | $ 940 M | ||
|
Nephros
NEPH
|
$ 3.96 | 2.33 % | $ 41.1 M | ||
|
electroCore
ECOR
|
$ 7.79 | 2.3 % | $ 43 K | ||
|
STERIS plc
STE
|
$ 244.17 | 0.34 % | $ 24.1 B | ||
|
Envista Holdings Corporation
NVST
|
$ 28.35 | -1.12 % | $ 4.76 B | ||
|
Teleflex Incorporated
TFX
|
$ 120.22 | -1.58 % | $ 5.36 B | ||
|
ICU Medical
ICUI
|
$ 142.8 | 0.1 % | $ 3.52 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.45 | 2.94 % | $ 195 M | ||
|
Intuitive Surgical
ISRG
|
$ 501.85 | 0.89 % | $ 179 B | ||
|
Repligen Corporation
RGEN
|
$ 125.74 | 2.18 % | $ 7.01 M | ||
|
Merit Medical Systems
MMSI
|
$ 74.29 | -0.75 % | $ 4.39 B | ||
|
STAAR Surgical Company
STAA
|
$ 18.7 | -1.14 % | $ 927 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
OraSure Technologies
OSUR
|
$ 3.0 | 0.8 % | $ 223 M | ||
|
Utah Medical Products
UTMD
|
$ 66.82 | 0.47 % | $ 242 M | ||
|
Pro-Dex
PDEX
|
$ 48.57 | 2.23 % | $ 160 M | ||
|
West Pharmaceutical Services
WST
|
$ 249.17 | -0.81 % | $ 18 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 13.42 | 0.9 % | $ 2.68 B | ||
|
Stereotaxis
STXS
|
$ 2.19 | 2.34 % | $ 177 M | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -0.28 % | $ 22.3 M |